TABLE 3

Adverse events and their CTCAE grades

Adverse eventFrequency by CTCAE grade (no. of patients [%])aP value
Conventional-dose group (n = 36)Low-dose group (n = 41)
All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3
Rash4 (11.1)3 (8.3)5 (12.2)1 (2.4)0.840.24
Fever3 (8.3)1 (2.8)1 (2.4)0 (0)0.240.28
Anorexia4 (11.1)2 (5.6)6 (14.6)0 (0)0.910.13
Vomiting4 (11.1)1 (2.8)0 (0)0 (0)0.030.28
Decreased white blood cell count3 (8.3)0 (0)4 (9.8)2 (4.9)0.830.18
Decreased neutrophil count2 (5.6)1 (2.8)4 (9.8)2 (4.9)0.490.63
Anemia8 (22.2)1 (2.8)7 (17.1)0 (0)0.570.28
Decreased platelet count10 (27.8)6 (16.7)4 (9.8)1 (2.4)0.080.03
Increased aspartate aminotransferase7 (19.4)0 (0)10 (24.4)0 (0)0.81NA
Increased alanine aminotransferase8 (22.2)1 (2.8)10 (24.4)0 (0)0.960.28
Increased creatinine12 (33.3)0 (0)8 (19.5)0 (0)0.17NA
Hyponatremia12 (33.3)4 (11.1)11 (26.8)1 (2.4)0.530.12
Hyperkalemia12 (33.3)4 (11.1)14 (34.1)5 (12.2)0.940.88
  • a CTCAE, Common Terminology Criteria for Adverse Events; NA, not applicable.